Amneal Pharmaceuticals ( (AMRX) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Amneal Pharmaceuticals’ stock has been on the rise following a Buy rating from Goldman Sachs, which set a price target of $12, driven by expected growth in their generics segment and a robust product pipeline. Despite a recall of three lots of Sulfamethoxazole/Trimethoprim tablets due to contamination concerns, the company’s strong Q1 2025 results and recent FDA approvals have kept investor sentiment positive.
More about Amneal Pharmaceuticals
YTD Price Performance: -7.60%
Average Trading Volume: 1,903,387
Technical Sentiment Signal: Hold
Current Market Cap: $2.26B
For further insights into AMRX stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.